One might argue that the B16F10 model may not fully represent the BRAF/RASWT melanomas that usually harbor NF1 mutation or deletion, KIT mutation, or amplification of cyclin D. Certainly extension of the study to more representative murine models could provide additional information as to how various genetic modifications affect response to CDK4/6 and CDK2 inhibitors. The gene discussed is NF1; the disease is melanoma.